Key clinical point: Nivolumab plus ipilimumab could be cost effective versus sunitinib in the first-line treatment of patients with mRCC.
Major finding: After analysis, the combination was estimated to cost $108,363 per quality-adjusted life-year (QALY) gained.
Study details: A cost-effectiveness analysis of 1,096 patients with intermediate- and poor-risk mRCC treated with first-line nivolumab plus ipilimumab.
Disclosures: The study was supported by funding from the National Natural Science Foundation of China and the Health and Family Planning Commission of Hunan province. The authors reported no conflicts of interest.
Wan X et al. JAMA Oncol. 2019 Feb 21. doi: 10.1001/jamaoncol.2018.7086.